The efficacy of an antitumor nucleoside, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (3'-ethynylcytidine, ECyd), was analyzed in vitro and in vivo. The in vivo antitumor effect of ECyd encapsulated into long-circulating liposomes was also examined. Based on pharmacokinetic (PK) and pharmacodynamic (PD) analyses, a model that quantitatively explains the in vivo effects of ECyd was proposed, using the concept of minimum effective concentration. The model suggests that ECyd followed a time-dependent mechanism of action in vivo, and that availability of ECyd in tumor tissue was highly important. To improve the availability of ECyd, its phospholipid derivatives were synthesized and encapsulated into long-circulating liposomes, which increased the antitumor effect. These results indicate that it is very important to design carriers of antitumor drugs based on PK-PD modeling.
Introduction
Antitumor drugs are classified into two groups based on their dose-dependencies [Shimoyama, 1975; Ozawa et al., 1988 Ozawa et al., , 1989 . One is a concentration-dependent drug group, which includes alkylating agents, intercalators and platinum derivatives (type I). Their cytotoxic effect depends on both concentration and exposure time, namely, on the area under the concentration-time curve (AUC). Thus, short exposure to these drugs at high concentration, and long exposure at low concentration, results in similar cytotoxicity. The other group is the exposure time-dependent drug group, which includes antimetabolites and vinca alkaloids (type II). Their cytotoxicity requires a certain exposure period, and short exposure at high concentration does not exert sufficient antitumor activity. Based on studies by Sugiyama's group, cell-cycle independent and dependent antitumor drugs are classified into type I and type II groups, respectively [Ozawa et al., 1988 [Ozawa et al., , 1989 ].
The type I antitumor drugs can be expected to be more effective when a drug delivery system (DDS) increases their AUC. Liposomes are a candidate for useful carriers that encapsulate water-soluble drugs into the aqueous phase and lipid-soluble drugs into the lipid membrane. Polyethylene glycol (PEG)ylation can dramatically prolong liposome circulation time in blood by preventing the absorption of liposomes onto opsonins, serum proteins [Blume and Cevc, 1990; Klibanov et al. 1990; Allen et al., 1991] . Unmodified liposomes disappear from blood circulation due to entrapment by reticuloendothelial system (RES) organs, such as liver and spleen, before they reach tumor tissue. On the other hand, PEGylated long-circulating liposomes can deliver antitumor drugs to tumor tissue by escaping from 4 recognition by opsonins in blood. The long circulation of the PEG-liposomes is also expected to enhance the antitumor effects of type II drugs, since they can be released for a longer period. Doxorubicin (Dox) and vincristine, AUC-dependent type I and AUC-independent type II antitumor drugs, respectively, have been shown to have enhanced activity after encapsulation into long-circulating liposomes [Papahadjopoulos et al., 1991; Vaage et al., 1993 ].
An antitumor nucleoside, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (3'-ethynylcytidine, ECyd) ( Fig. 1) , exerts its cytotoxic effect by transcription inhibition and apoptosis induction [Hattori et al., 1996; Tabata et al., 1997; Takatori et al., 1998 Takatori et al., , 1999 . ECyd is phosphorylated by uridine-cytidine kinase 2 (UCK2) to form the monophosphate derivative (ECMP), and subsequent phosphorylation reactions yield the actual drug, ECTP, the triphosphate derivative [Shimamoto et al., 2002a [Shimamoto et al., , 2002b . The action mechanism of ECyd (ECTP) is inhibition of RNA polymerases, resulting in the disturbance of various cellular events. Thus, ECyd is thought to be independent of the cell cycle and a type I drug (AUC-dependent). Thus, the encapsulation of ECyd into long-circulating liposomes could enhance its antitumor effect as that of the AUC-dependent type I antitumor drug, Dox.
To design excellent carriers of antitumor drugs, analysis of their antitumor effects based on the physiological model is important. However, such DDS design has rarely been reported. Previously, one of the authors (H. H.) analyzed liposomal Dox based on the model and found that optimization of its release rate is an important factor in the enhancement of the antitumor effect [Tsuchihashi et al., 1999; Harashima et al., 1999] .
In this study, the antitumor effect of ECyd was analyzed in vitro and in vivo. The 5 antitumor effect of ECyd encapsulated in long-circulating liposomes was also examined.
Based on in vivo pharmacokinetic (PK)-pharmacodynamic (PD) analyses, a physiological model that could explain its in vivo antitumor effect quantitatively was proposed. The model suggested that ECyd followed a time-dependent mechanism of action in vivo (in contrast to in vitro), and that the availability of ECyd in tumor tissue is highly important. To increase the availability of ECyd, its phospholipid derivatives were synthesized and encapsulated into long-circulating liposomes. These liposomes successfully increased the antitumor effect.
These results indicate that the design of carriers of antitumor drugs based on their physiological models is highly important.
Materials and methods

Materials
ECyd was synthesized as described previously [Hattori et al., 1996] . Colon 26 cells were provided by Taiho Pharmaceutical Co. (Tokyo, Japan).
Chemical synthesis of phospholipid derivatives of ECyd
A mixture of a solution of 3-sn-diacylphosphatidylcholine (dipalmitoyl-, distearoyl-, or dioleoyl-phosphatidylcholine, 3.4 mmol) in CHCl 3 (50 mL), phospholipase D (PLDP, Asahi Kasei Co., Tokyo, Japan) (60 mg, 10,800 units) and a solution of ECyd (4.54 g, 17 6 mmol) in sodium acetate buffer (pH 4.5, 200 mM, 25 ml) was stirred at 40 °C for 2.5 h.
CHCl 3 (60 mL), MeOH (60 mL) and water (10 mL) were added to the resulting mixture, and the organic layer was evaporated. The residue was purified on a silica gel column (33-50% MeOH in CHCl 3 ). The fractions containing the desired product were collected and evaporated.
The residue was dissolved in a mixture of CHCl 3 -MeOH-water (10/5/1), loaded on a WK-20 (Na + form) column and eluted using the same mixed solvent. 
In vitro chemosensitivity test
The growth-inhibitory effects of ECyd on mouse colorectal carcinoma cells were determined by colorimetric assay. Colon 26 cells (5.0 X 10 4 cells/well) were grown in RPMI-1640 medium with 10% fetal calf serum (100 µl) under a 5% CO 2 / 95% air atmosphere at 37 °C. After 24 hr, the cells were exposed to ECyd at various concentrations for the time periods indicated. The medium containing ECyd was replaced every 12 hr. After exposure to the drug, cells were washed with the medium twice, and then incubated in 100 µl of the medium at 37 °C up to 48 hr after exposure initiation. The medium was removed, 110 µl of TetraColor One (Seikagaku Co., Tokyo, Japan) was added to each well, and the cell cultures were incubated at 37 °C for 3 hr. The absorbance of each well was measured at 450 nm using a Benchmark Plus (BIO-RAD, Hercules, California, USA). The 50% inhibitory concentration (IC 50 ) was determined from the dose-response curve.
In vivo antitumor activity
Colon 26 cells (1 X 10 7 cells/mouse) were transplanted hypodermically into 5-week-old male BALB/c mice on day 0. ECyd, or liposomes encapsulating ECyd, were intravenously administered to tumor-bearing BALB/c mice on days 5 and 10, or on day 8.
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Tumors were collected on day 15 from ether-anesthetized mice, and the averaged volumes of tumors in the administered mice were calculated. The inhibition ratio (IR) was calculated using the equation below:
(eq. 1)
Pharmacokinetics of free ECyd
Colon 26 concentration in blood and the amount in tumor were measured as described above.
Computational simulations
The pharmacokinetic data were analyzed using SAAM II (SAAM Institute, Seattle, WA, USA) and Stella (High Performance Systems, Hanover, NH, USA) software.
The mass balance equations for free ECyd (Scheme 1A) are as follows:
The mass balance equations for free ECyd upon liposomal ECyd injection (Scheme 1A) are as follows:
The mass balance equations for liposomal ECyd upon liposomal ECyd injection (Scheme 1A)
are as follows: 
Results
AUC-dependence of the cytotoxic effects of ECyd in vitro
The were injected (data not shown), indicating the linearity of the drug disposition under our experimental conditions. Importantly, ECyd was cleared rapidly from blood.
AUC-independence of the antitumor effects of ECyd in vivo
Various doses of ECyd were then intravenously administered to tumor-bearing BALB/c mice on days 5 and 10 (double administration), or day 8 (single administration).
Tumors were collected on day 15 and the IR values were determined. In contrast to the expectations based on the in vitro cytotoxic effect (Supplementary 
PK-PD modeling of ECyd
PK parameters were obtained by curve-fitting based on the three-compartment model shown in Scheme 1A (see "Free ECyd") and the actual ECyd dose data in blood and tumor tissue ( Fig. 2A and B) , according to the equations described in the Materials and
Methods section. The PK parameters obtained are shown in Table 2 . The linearity of the ECyd disposition under these conditions was observed, and the same values of the parameters were used in the following simulations.
To explain the fact that the antitumor effect of ECyd was AUC-dependent in vitro and AUC-independent in vivo (Supplementary Table 1 and Table 1 , Experiment 1), the presence of a minimum effective concentration (C min ) was introduced as a new parameter. We hypothesized that ECyd can exert antitumor effect only when free concentration of ECyd exceeds the C min in tumor tissue (Scheme 1B). However, since we could not measure the C min ,
we estimated the C min based on the simulation as explained below. The putative C min value was changed in the simulation, and the effective time within which the ECyd concentration in the tumor was above C min was calculated for each C min value. We then examined the curve-fitting of calculated effective times and the actually observed IR values, using the following equation
where E max , t, and t 50 represent the maximum efficacy (set as 100%), effective time, and 50% inhibitory time, respectively. In the case of double administration, the calculated effective time was doubled. As shown in Fig. 3B , the IR data of the single and double administration experiments fitted well as the function of effective time when C min was set at 61.1 fmol/g (the t 50 and r values were calculated as 147.5 hr and 2.9, respectively). Thus, the threshold value C min could well explain the in vivo antitumor effects of ECyd.
The antitumor effects of liposomal ECyd in vivo
The results shown above suggest that the antitumor effect of ECyd would be enhanced by encapsulation into long-circulating liposomes and prolonged exposure of tumor cells to ECyd above C min . PEGylated liposomes containing ECyd were then prepared. The encapsulation ratio was 5%. Liposomal ECyd was administered as free ECyd to tumor-bearing BALB/c mice on days 5 and 10 (double administration) or on day 8 (single administration). Unexpectedly, however, liposomal ECyd inhibited tumor growth less efficiently than unencapsulated ECyd, irrespective of the injection schedule (Table 1, Experiment 2).
PK-PD modeling of liposomal ECyd
IR = Emax X t r t50 r + t r 15
To determine the reason the liposomal ECyd was unexpectedly less effective than free ECyd, the PK of liposomal ECyd was analyzed. Both the liposome membrane and ECyd were traced after administration. As shown in Fig. 2C , ~10% of liposomes modified with PEG were present in blood after 24 hr, showing the nature of long-circulating liposomes. Nearly 10% of the injected liposomes reached tumor tissue at 24 hr (Fig. 2D) . The disposition of total ECyd, which includes released and liposomal ECyd, is also shown in Figures 2C and D . The amounts of total ECyd in blood and tumor were not identical to those of liposomes, indicating the release of ECyd from liposomes. We had hypothesized that ECyd released in and near the tumor would accumulate in the tumor. However, the amount of ECyd was half that of the liposomes in the tissue. As described above, the liposomal ECyd injection was less effective than free ECyd injection (Table 2 , Experiments 1 and 2). Taken together, these results suggest that the free ECyd concentration in the tumor was lower for the liposomal ECyd injection than for the free ECyd injection.
A PK model containing liposomal and free ECyd (Scheme 1A) was then constructed, and curve-fitting was carried out based on this model and the actual data. First, the data on [ combination of two functions that appear to reflect fast and slow releases of ECyd from liposomes. These two release rates might be due to the presence of multilamellar and unilamellar vesicles. The release rate constant (k rel,tumor ) was calculated to be 0.02 hr -1 , a three-fold higher value than the rate constant of the slow release in blood (k rel,blood,slow ) ( Table 2 and Scheme 1A). Effective times for which tumor cells were exposed to free ECyd above the C min value (61.1 fmol/g) obtained from the free ECyd injection data and the simulation were calculated ( Fig. 2A and B, and Fig. 3B ). The IR data from the single injections of the liposomal ECyd were on/near the effective time-IR curve (Fig. 3C, circles) . In contrast, data from the double injections of the liposomal ECyd were out of the curve (triangles). It has been reported that second injections of PEG-liposomes are cleared rapidly from blood (accelerated blood clearance (ABC) phenomenon) [Dams et al., 2000; Laverman et al., 2001; Ishida et al., 2003a Ishida et al., , 2003b . The actual effective times for double administration might be half of those in the simulation, owing to the ABC phenomenon of the second injection of liposomes. The insufficient antitumor activity and the simulation suggest that the PEG-liposomes did not deliver free ECyd to the tumor more efficiently than the free ECyd injection. These results indicate that the availability of "free" ECyd in the tumor tissue is important.
Enzymatic synthesis of the phospholipid derivatives of ECyd
The simulations based on the PK data of free and liposomal ECyd prompted the use of ECyd-phospholipid derivatives that may improve delivery to the tumor and availability in the tumor. Three ECyd-phospholipid derivatives were prepared, in which phospholipids were attached to ECyd via the 5'-phosphate (Fig. 1) . The ECyd-phospholipid derivatives have affinity to the cell membrane, and might move from liposomes to the cell membrane. The derivatives on the inner membrane might release the monophosphate derivative of ECyd (ECMP) into the cytosol of tumor cells. This might overcome the important barriers of uptake by transporter(s) and 5'-phosphorylation by UCK2. Controlled release of ECMP from the phospholipid derivatives might be useful, since the first phosphorylation of nucleoside analogs is a determining factor for their efficacy [Matsuda and Sasaki, 2004 ].
An enzymatic method was previously developed for the preparation of phospholipid derivatives of nucleosides from a nucleoside and a phosphatidylcholine by a one-step reaction, in which phospholipase D-catalyzed transphosphatidylation, namely, the regiospecific transfer reaction of the phosphatidyl residue from a phosphatidyalcholine to the 5'-hydroxyl of a nucleoside, was used [Shuto et al., 1987] . The phospholipid derivatives of ECyd used in this study were effectively synthesized by this method.
The improved antitumor effects of liposomes containing ECyd-phospholipid derivative
Liposomes containing ECyd-phospholipid were administered to tumor-bearing mice.
As shown in Table 1 
Discussion
The antitumor effect of ECyd was AUC-dependent in vitro and time-dependent in vivo (Supplementary Table 1 and Table 1 , Experiment 1). It appears that the efficacy of ECyd actually depends on both concentration and time, and that apparent dependency changes with the experimental conditions. ECyd is taken up into cells by transporters [Endo et al., 2007] and phosphorylated by UCK2 to ECMP [Shimamoto et al., 2002a [Shimamoto et al., , 2002b . The actual drug, ECTP, is formed by subsequent phosphorylation reactions from ECMP, but the first phosphorylation reaction would be most important for the efficacy of ECyd. The incorporated
ECyd is excreted from cells by transporter(s). When measured in vitro, the influx clearance of
ECyd was lower than its efflux clearance, suggesting the presence of efflux transporter(s) (data not shown). However, it is possible that the phosphorylated forms of ECyd are hardly excreted. The conversion of ECyd to ECMP by UCK2 would not occur substantially at low extracellular ECyd concentrations because of the efflux transporter(s). Thus, an amount of ECyd higher than a certain "threshold" would be required for the cytotoxic effect, and totally synthesized ECTP should be dependent on both its extracellular ECyd concentration and exposure time. This could be a reason for the AUC-dependency of ECyd in vitro Table 1 ).
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Considering that the uptake of ECyd and its conversion to ECMP are carried out by enzymes, saturation of their activities can be easily assumed. A highly excessive amount of ECyd would not lead to dose-dependent accumulation of ECTP. Therefore, dose-dependency of the efficacy would be present within a certain concentration range. In vitro, extracellular
ECyd concentration is thought to be constant during the exposure time, due to a lack of clearance from the medium. On the other hand, the half life of ECyd in blood was very short, and ECyd concentration in the tumors varied, increasing and then decreasing ( Fig. 2A and B ).
Tumor cells near blood vessels, in particular, would be exposed transiently to a high concentration of ECyd. In this study, a putative concentration value, C min , was proposed in the simulation to explain the schedule-dependency of the ECyd antitumor effect in vivo. The calculated effective time based on this value could explain the efficacy of free and liposomal ECyd ( Fig. 3B and C) . Since the uptake, excretion, and phosphorylation of ECyd are conducted by enzymes, as described above, a simple linear correlation between AUC and IR would not be present. In such cases, the concept of C min might be a good parameter to explain the efficacy of other drugs.
Calculation of release rates of ECyd from PEG-liposomes showed the presence of two values (Table 2 and Supplementary Fig. 1 ). The k rel,blood,fast and k rel,blood,slow values were calculated to be 0.52 and 0.006 hr -1 , respectively. These two release rates could be attributed to the possible presence of two fractions of liposomes, multilamellar and unilamellar vesicles.
The fast rates would reflect ECyd release from the outermost aqueous phase. The release rate constant in tumor tissue (k rel,tumor ) was calculated to be a three-fold higher value of the rate 20 constant of the slow release in blood (k rel,blood,slow ). This suggests that certain collapse mechanism(s) of liposomes, such as phagocytization by macrophages, are present near the tumor. Different drug release rates in blood and tumor are suggested in this study, although the same release rates were hypothesized in previous studies by Harashima et al. [Tsuchihashi et al., 1999; Harashima et al., 1999] .
Single and double administration of ECyd encapsulated in PEG-liposomes was less effective than injection of ECyd alone (Table 1 , Experiments 1 and 2). PK analyses indicate that the apparent ECyd concentration in tumor was higher for liposomal ECyd than for ECyd alone ( Fig. 2B and D) . However, the simulation based on the model shown in Scheme 1A
suggests that ~75% of ECyd was present in the encapsulated form in tumor tissue (data not shown). This would result in the reduction of the availability of ECyd in the tumor for liposomal ECyd. Thus, it should be emphasized that disposition in a target site, but not in blood, is important for the design of the optimal carrier of a drug.
The simulations based on the PK data of free and liposomal ECyd prompted the use of ECyd-phospholipid derivatives for improvement of the trafficking to and availability in the tumor tissue. Indeed, the liposomes containing DPPECyd and DSPECyd showed increased antitumor effects compared with free ECyd (Table 1 Table 1 Inhibition of tumor growth by administration of Ecyd and its derivatives. ----------------------------------------------------------------------- 
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